Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome

Abstract

Eosinophils play a key role in orchestrating the complex clinicopathological pulmonary and extrapulmonary disease features in patients with eosinophilic syndromes. Eosinophilic pulmonary syndromes consist of a heterogeneous group of disorders characterized by the presence of peripheral blood eosinophilia and/or eosinophilic-related pulmonary impairment. These disorders can present with varying degrees of organ involvement, and while their presentation may be similar, it is important to define the disease state, as management and prognosis differ. In this article, we discuss acute and chronic eosinophilic pneumonias, eosinophilic granulomatosis with polyangiitis, and the hypereosinophilic syndromes. The mainstay of therapy for these disorders has been corticosteroids; however, recent and ongoing studies have provided strong grounds for optimism for specific targeted treatment approaches.

Keywords

eosinophilic lung diseases - acute eosinophilic pneumonia - chronic eosinophilic pneumonia - eosinophilic granulomatosis with polyangiitis - Churg–Strauss syndrome - allergic granulomatosis and angiitis - hypereosinophilic syndromes

• References

• 1 Jones AL, Hume R, Bamforth KJ, Coughtrie MW. Estrogen and phenol sulfotransferase activities in human fetal lung. Early Hum Dev 1992; 28 (1) 65-77
• 2 Kariyawasam HH, Robinson DS. The role of eosinophils in airway tissue remodelling in asthma. Curr Opin Immunol 2007; 19 (6) 681-686
• 3 Gomes I, Mathur SK, Espenshade BM, Mori Y, Varga J, Ackerman SJ. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol 2005; 116 (4) 796-804
• 4 Brigden M, Graydon C. Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med 1997; 121 (9) 963-967
• 5 Rothenberg ME. Eosinophilia. N Engl J Med 1998; 338 (22) 1592-1600
• 6 Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006; 133 (5) 468-492
• 7 Shorr AF, Scoville SL, Cersovsky SB , et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA 2004; 292 (24) 2997-3005
• 8 Miki K, Miki M, Nakamura Y , et al. Early-phase neutrophilia in cigarette smoke-induced acute eosinophilic pneumonia. Intern Med 2003; 42 (9) 839-845
• 9 Watanabe K, Fujimura M, Kasahara K , et al. Acute eosinophilic pneumonia following cigarette smoking: a case report including cigarette-smoking challenge test. Intern Med 2002; 41 (11) 1016-1020
• 10 Philit F, Etienne-Mastroïanni B, Parrot A, Guérin C, Robert D, Cordier JF. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002; 166 (9) 1235-1239
• 11 Rhee CK, Min KH, Yim NY , et al. Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J 2013; 41 (2) 402-409
• 12 Rom WN, Weiden M, Garcia R , et al. Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. Am J Respir Crit Care Med 2002; 166 (6) 797-800
• 13 Respiratory failure and eosinophilia in a young man. Am J Med 1993; 94 (5) 533-542
• 14 Brander PE, Tukiainen P. Acute eosinophilic pneumonia in a heroin smoker. Eur Respir J 1993; 6 (5) 750-752
• 15 Kondo K, Inoue Y, Hamada H, Yokoyama A, Kohno N, Hiwada K. Acetaminophen-induced eosinophilic pneumonia. Chest 1993; 104 (1) 291-292
• 16 Mahatma M, Haponik EF, Nelson S, Lopez A, Summer WR. Phenytoin-induced acute respiratory failure with pulmonary eosinophilia. Am J Med 1989; 87 (1) 93-94
• 17 Oh PI, Balter MS. Cocaine induced eosinophilic lung disease. Thorax 1992; 47 (6) 478-479
• 18 Poe RH, Condemi JJ, Weinstein SS, Schuster RJ. Adult respiratory distress syndrome related to ampicillin sensitivity. Chest 1980; 77 (3) 449-451
• 19 Sovijärvi AR, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis 1977; 58 (1) 41-50
• 20 Strumpf IJ, Drucker RD, Anders KH, Cohen S, Fajolu O. Acute eosinophilic pulmonary disease associated with the ingestion of L-tryptophan-containing products. Chest 1991; 99 (1) 8-13
• 21 Pope-Harman AL, Davis WB, Allen ED, Christoforidis AJ, Allen JN. Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. Medicine (Baltimore) 1996; 75 (6) 334-342
• 22 Jhun BW, Kim SJ, Kim K, Lee JE. Clinical implications of initial peripheral eosinophilia in acute eosinophilic pneumonia. Respirology 2014; 19 (7) 1059-1065
• 23 Daimon T, Johkoh T, Sumikawa H , et al. Acute eosinophilic pneumonia: Thin-section CT findings in 29 patients. Eur J Radiol 2008; 65 (3) 462-467
• 24 Tazelaar HD, Linz LJ, Colby TV, Myers JL, Limper AH. Acute eosinophilic pneumonia: histopathologic findings in nine patients. Am J Respir Crit Care Med 1997; 155 (1) 296-302
• 25 Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150 (4) 967-972
• 26 Sveinsson OA, Isaksson HJ, Gudmundsson G. Chronic eosinophilic pneumonia in Iceland: clinical features, epidemiology and review. Laeknabladid 2007; 93 (2) 111-116
• 27 Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 2001; 32: 114s-118s
• 28 Marchand E, Reynaud-Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Medicine (Baltimore) 1998; 77 (5) 299-312
• 29 Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore) 1988; 67 (3) 154-162
• 30 Naughton M, Fahy J, FitzGerald MX. Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest 1993; 103 (1) 162-165
• 31 Mayo JR, Müller NL, Road J, Sisler J, Lillington G. Chronic eosinophilic pneumonia: CT findings in six cases. AJR Am J Roentgenol 1989; 153 (4) 727-730
• 32 Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR Am J Roentgenol 1977; 128 (1) 1-13
• 33 Pesci A, Bertorelli G, Manganelli P , et al. Bronchoalveolar lavage in chronic eosinophilic pneumonia. Analysis of six cases in comparison with other interstitial lung diseases. Respiration 1988; 54 (Suppl. 01) 16-22
• 34 Durieu J, Wallaert B, Tonnel AB. Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia. Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J 1997; 10 (2) 286-291
• 35 Marchand E, Etienne-Mastroianni B, Chanez P, Lauque D, Leclerc P, Cordier JF ; Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires. Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other?. Eur Respir J 2003; 22 (1) 8-13
• 36 Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27 (2) 277-301
• 37 Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49 (3) 388-393
• 38 Vinit J, Muller G, Bielefeld P , et al. Churg-Strauss syndrome: retrospective study in Burgundian population in France in past 10 years. Rheumatol Int 2011; 31 (5) 587-593
• 39 Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46 (8) 1329-1337
• 40 Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009; 48 (12) 1560-1565
• 41 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53 (1) 93-99
• 42 Harrold LR, Andrade SE, Go AS , et al. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005; 32 (6) 1076-1080
• 43 Loughlin JE, Cole JA, Rothman KJ, Johnson ES. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol 2002; 88 (3) 319-325
• 44 Tsurikisawa N, Morita S, Tsuburai T , et al. Familial Churg-Strauss syndrome in two sisters. Chest 2007; 131 (2) 592-594
• 45 Manganelli P, Giacosa R, Fietta P, Zanetti A, Neri TM. Familial vasculitides: Churg-Strauss syndrome and Wegener's granulomatosis in 2 first-degree relatives. J Rheumatol 2003; 30 (3) 618-621
• 46 Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63 (2) 65-81
• 47 Solans R, Bosch JA, Pérez-Bocanegra C , et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40 (7) 763-771
• 48 Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78 (1) 26-37
• 49 Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115 (4) 284-290
• 50 Dennert RM, van Paassen P, Schalla S , et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010; 62 (2) 627-634
• 51 Hasley PB, Follansbee WP, Coulehan JL. Cardiac manifestations of Churg-Strauss syndrome: report of a case and review of the literature. Am Heart J 1990; 120 (4) 996-999
• 52 Pelà G, Tirabassi G, Pattoneri P, Pavone L, Garini G, Bruschi G. Cardiac involvement in the Churg-Strauss syndrome. Am J Cardiol 2006; 97 (10) 1519-1524
• 53 Neumann T, Manger B, Schmid M , et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88 (4) 236-243
• 54 Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318 (25) 1651-1657
• 55 Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53 (3) 796-798
• 56 Sinico RA, Di Toma L, Maggiore U , et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52 (9) 2926-2935
• 57 Reid AJ, Harrison BD, Watts RA, Watkin SW, McCann BG, Scott DG. Churg-Strauss syndrome in a district hospital. QJM 1998; 91 (3) 219-229
• 58 Della Rossa A, Baldini C, Tavoni A , et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002; 41 (11) 1286-1294
• 59 Sinico RA, Di Toma L, Maggiore U , et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47 (5) 770-779
• 60 Choi YH, Im JG, Han BK, Kim JH, Lee KY, Myoung NH. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest 2000; 117 (1) 117-124
• 61 Worthy SA, Müller NL, Hansell DM, Flower CD. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR Am J Roentgenol 1998; 170 (2) 297-300
• 62 Chumbley LC, Harrison Jr EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977; 52 (8) 477-484
• 63 Guillevin L, Guittard T, Bletry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 1987; 165 (3) 165-172
• 64 Silva CI, Müller NL, Fujimoto K, Johkoh T, Ajzen SA, Churg A. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging 2005; 20 (2) 74-80
• 65 Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung. A review. Am J Clin Pathol 2000; 114 (5) 767-772
• 66 Masi AT, Hunder GG, Lie JT , et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33 (8) 1094-1100
• 67 Jennette JC, Falk RJ, Andrassy K , et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37 (2) 187-192
• 68 Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98 (2) 97-111
• 69 Watts R, Lane S, Hanslik T , et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66 (2) 222-227
• 70 Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P ; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90 (1) 19-27
• 71 Morgan JM, Raposo L, Gibson DG. Cardiac involvement in Churg-Strauss syndrome shown by echocardiography. Br Heart J 1989; 62 (6) 462-466
• 72 Ramakrishna G, Connolly HM, Tazelaar HD, Mullany CJ, Midthun DE. Churg-Strauss syndrome complicated by eosinophilic endomyocarditis. Mayo Clin Proc 2000; 75 (6) 631-635
• 73 Stöllberger C, Finsterer J, Winkler WB. Eosinophilic pericardial effusion in Churg-Strauss syndrome. Respir Med 2005; 99 (3) 377-379
• 74 Val-Bernal JF, Mayorga M, García-Alberdi E, Pozueta JA. Churg-Strauss syndrome and sudden cardiac death. Cardiovasc Pathol 2003; 12 (2) 94-97
• 75 Moosig F, Bremer JP, Hellmich B , et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72 (6) 1011-1017
• 76 Cohen P, Pagnoux C, Mahr A , et al; French Vasculitis Study Group. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57 (4) 686-693
• 77 Stone JH, Merkel PA, Spiera R , et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (3) 221-232
• 78 Umezawa N, Kohsaka H, Nanki T , et al. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG. Mod Rheumatol 2014; 24 (4) 685-687
• 79 Mohammad AJ, Hot A, Arndt F , et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2016; 75 (2) 396-401
• 80 Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain 1989; 112 (Pt 6) 1533-1548
• 81 Fanouriakis A, Kougkas N, Vassilopoulos D, Fragouli E, Repa A, Sidiropoulos P. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Semin Arthritis Rheum 2015; 45 (1) 60-66
• 82 Jones RB, Ferraro AJ, Chaudhry AN , et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60 (7) 2156-2168
• 83 Jayne DR, Gaskin G, Rasmussen N , et al; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18 (7) 2180-2188
• 84 Pepper RJ, Chanouzas D, Tarzi R , et al; European Vasculitis Study (EUVAS) investigators. Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8 (2) 219-224
• 85 Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125 (6) 1336-1343
• 86 Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155 (5) 341-343
• 87 Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg Strauss syndrome—successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22 (6) (Suppl. 36) S52-S61
• 88 Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 2010; 28 (1) (Suppl. 57) 24-30
• 89 Tsurikisawa N, Taniguchi M, Saito H , et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92 (1) 80-87
• 90 Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206 (5) 496-501
• 91 Pabst S, Tiyerili V, Grohé C. Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg-Strauss syndrome. Thorax 2008; 63 (8) 747-748
• 92 Graziani A, Quercia O, Girelli F, Martelli A, Mirici Cappa F, Stefanini GF. Omalizumab treatment in patient with severe asthma and Eosinophilic Granulomatosis with Polyangiitis. A case report. Eur Ann Allergy Clin Immunol 2014; 46 (6) 226-228
• 93 Baughman RP, Meyer KC, Nathanson I , et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 142 (5) e1S-e111S
• 94 Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968; 68 (6) 1220-1229
• 95 Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54 (1) 1-27
• 96 Valent P, Klion AD, Horny HP , et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130 (3) 607-612.e9
• 97 Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010; 126 (1) 179-181
• 98 Roufosse F. Management of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2015; 35 (3) 561-575
• 99 Klion A. Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 2009; 60: 293-306
• 100 Klion AD, Robyn J, Akin C , et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103 (2) 473-478
• 101 Klion AD, Noel P, Akin C , et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101 (12) 4660-4666
• 102 Gotlib J. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87 (9) 903-914
• 103 Cools J, DeAngelo DJ, Gotlib J , et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13) 1201-1214
• 104 Pardanani A, Ketterling RP, Li CY , et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30 (8) 965-970
• 105 Ogbogu PU, Bochner BS, Butterfield JH , et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124 (6) 1319-25.e3
• 106 Score J, Curtis C, Waghorn K , et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20 (5) 827-832
• 107 Cheah CY, Burbury K, Apperley JF , et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123 (23) 3574-3577
• 108 Curtis CE, Grand FH, Musto P , et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138 (1) 77-81
• 109 Legrand F, Renneville A, Macintyre E , et al; on behalf of the French Eosinophil Network. The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore) 2013; 92 (5)
• 110 Parrillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med 1979; 67 (4) 572-582
• 111 Spiegel R, Miron D, Fink D, Gavriel H, Horovitz Y. Eosinophilic pericarditis: a rare complication of idiopathic hypereosinophilic syndrome in a child. Pediatr Cardiol 2004; 25 (6) 690-692
• 112 Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: still more heterogeneity. Curr Opin Immunol 2005; 17 (6) 679-684
• 113 Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000; 105 (4) 651-663
• 114 Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007; 27 (3) 357-375
• 115 Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330 (8) 535-538
• 116 Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85 (2) 158-164
• 117 Jovanovic JV, Score J, Waghorn K , et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109 (11) 4635-4640
• 118 Klion AD, Bochner BS, Gleich GJ , et al; The Hypereosinophilic Syndromes Working Group. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117 (6) 1292-1302
• 119 Pitini V, Arrigo C, Azzarello D , et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102 (9) 3456-3457 , author reply 3457
• 120 Pardanani A, Reeder T, Porrata LF , et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101 (9) 3391-3397
• 121 Metzgeroth G, Erben P, Martin H , et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012; 26 (1) 162-164
• 122 Al-Riyami AZ, Hudoba M, Young S, Forrest D. Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia. Leuk Lymphoma 2013; 54 (8) 1788-1790
• 123 Klion AD. How I treat hypereosinophilic syndromes. Blood 2015; 126 (9) 1069-1077
• 124 Hochhaus A, le Coutre PD, Kantarjian HM , et al. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol 2013; 139 (12) 1985-1993
• 125 Tabouret E, Charbonnier A, Mozziconacci MJ, Ivanov V. Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leuk Res 2011; 35 (1) 136
• 126 Imagawa J, Harada Y, Yoshida T , et al. Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib. Rinsho Ketsueki 2011; 52 (7) 546-550
• 127 Lierman E, Michaux L, Beullens E , et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23 (5) 845-851
• 128 Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin N Am 2007; 27: 357-375
• 129 Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 2009; 23: 157-165
• 130 Wechsler ME, Fulkerson PC, Bochner BS , et al. Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol 2012; 130: 563-571
• 131 Wills-Karp M, Luyimbazi J, Xu X , et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-2261 (Allergy 2015;8:87–92)
• 132 Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev Off J Eur Respir Soc 2010; 19: 46-54
• 133 Maselli DJ, Keyt H, Rogers L. Profile of lebrikizumab and its potential in the treatment of asthma. J Asthma Allergy 2015; 8: 87-92
• 134 Wenzel S, Ford L, Pearlman D , et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455-2466